Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Afd Pharmacoepi & Clinical Pharmacology"'
Autor:
Abedian, Shifteh, Abbasi, Ali, de Boer, Anthonius, Stricker, Bruno H, Bakker, Stephan J L, van der Harst, Pim, Sedaghat, Sanaz, Darvishian, Maryam, Ikram, M Arfan, Navis, Gerjan, Dehghan, Abbas, Pen, Ido, Stolk, Ronald P, Snieder, Harold, Klungel, Olaf H, Souverein, Patrick, Alizadeh, Behrooz Z, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology
Publikováno v:
Scientific Reports
Scientific Reports, 11(1). NLM (Medline)
Scientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
Scientific Reports, 11(1):2794. Nature Publishing Group
Scientific Reports, 11(1). NLM (Medline)
Scientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
Scientific Reports, 11(1):2794. Nature Publishing Group
Underlying genetic determinants contribute to developing type 2 diabetes (T2D) future diseases. The present study aimed to identify which genetic variants are associated with the incident of the major T2D co-morbid disease. First, we conducted a disc
Autor:
van der Wouden, Cathelijne H, Böhringer, Stefan, Cecchin, Erika, Cheung, Ka-Chun, Dávila-Fajardo, Cristina Lucía, Deneer, Vera H M, Dolžan, Vita, Ingelman-Sundberg, Magnus, Jönsson, Siv, Karlsson, Mats O, Kriek, Marjolein, Mitropoulou, Christina, Patrinos, George P, Pirmohamed, Munir, Rial-Sebbag, Emmanuelle, Samwald, Matthias, Schwab, Matthias, Steinberger, Daniela, Stingl, Julia, Sunder-Plassmann, Gere, Toffoli, Giuseppe, Turner, Richard M, van Rhenen, Mandy H, van Zwet, Erik, Swen, Jesse J, Guchelaar, Henk-Jan, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology
Publikováno v:
Pharmacogenetics and Genomics
Pharmacogenetics and Genomics, 30(6), 131-144. LIPPINCOTT WILLIAMS & WILKINS
Pharmacogenetics and Genomics, 30(6), 131. Lippincott Williams and Wilkins
Pharmacogenetics and Genomics, 30(6), 131-144. LIPPINCOTT WILLIAMS & WILKINS
Pharmacogenetics and Genomics, 30(6), 131. Lippincott Williams and Wilkins
Objectives Pharmacogenetic panel-based testing represents a new model for precision medicine. A sufficiently powered prospective study assessing the (cost-)effectiveness of a panel-based pharmacogenomics approach to guide pharmacotherapy is lacking.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b60c8c9f44e83005ec779a41bd258af
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-419196
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-419196
Autor:
de Jong, Corine, Herder, Gerarda J.M., Deneer, V.H.M., Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology
Publikováno v:
Thoracic Cancer, 11(12), 3634. Blackwell Publishing Asia Pty Ltd
Thoracic Cancer
Thoracic Cancer
Introduction Platinum-based chemotherapy is currently the most frequently applied first-line treatment for patients with advanced non-small cell lung cancer (NSCLC) without targetable mutations or high PD-L1 expression. Unfortunately, chemotherapy-in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27dc67ecca3f4e3068008de99e031849
https://dspace.library.uu.nl/handle/1874/410144
https://dspace.library.uu.nl/handle/1874/410144
Autor:
Broekman, Mark M.T.J., Coenen, Marieke J H, van Marrewijk, Corine J, Wanten, Geert J A, Wong, Dennis R, Verbeek, Andre L.M., Klungel, Olaf H., Hooymans, Piet M, Guchelaar, Henk-Jan, Scheffer, Hans, Derijks, Luc J J, De Jong, Dirk J., Pharmacoepidemiology and Clinical Pharmacology, Afd Pharmacoepi & Clinical Pharmacology
Publikováno v:
Inflammatory Bowel Diseases, 23, 10, pp. 1873-1881
Inflammatory Bowel Diseases, 23(10), 1873. John Wiley and Sons Inc.
Inflammatory Bowel Diseases, 23(10), 1873-1881
Inflammatory Bowel Diseases
Inflammatory Bowel Diseases, 23, 1873-1881
Inflammatory Bowel Diseases, 23(10), 1873. John Wiley and Sons Inc.
Inflammatory Bowel Diseases, 23(10), 1873-1881
Inflammatory Bowel Diseases
Inflammatory Bowel Diseases, 23, 1873-1881
Article first published online 20 june 2017. Supplemental Digital Content is Available in the Text.
Background: There are substantial global differences in the preference for mercaptopurine (MP) or its prodrug azathioprine (AZA) as first-choice
Background: There are substantial global differences in the preference for mercaptopurine (MP) or its prodrug azathioprine (AZA) as first-choice
Autor:
Henricks, Linda M, Opdam, Frans L, Beijnen, J H, Cats, A., Schellens, J H M, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology
Publikováno v:
Annals of Oncology, 28(12), 2915. Oxford University Press
The fluoropyrimidine anticancer drugs, especially 5-fluorouracil (5-FU) and capecitabine, are frequently prescribed for several types of cancer, including breast, colorectal, head and neck and gastric cancer. In the current drug labels of 5-FU and ca
Autor:
Amstutz, Ursula, Henricks, Linda M, Offer, Steven M, Barbarino, Julia, Schellens, Jan H M, Swen, Jesse J., Klein, Teri E, McLeod, Howard L, Caudle, Kelly E, Diasio, Robert B, Schwab, Matthias, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology
Publikováno v:
Clinical Pharmacology and Therapeutics, 103(2), 210. Nature Publishing Group
Clinical Pharmacology and Therapeutics, 103(2), 210-216
Clinical Pharmacology and Therapeutics, 103(2), 210-216
Fluoropyrimidines (5-fluorouracil, capecitabine) are the mainstay chemotherapeutic agents for the treatment of many types of cancer. Metabolism of fluoropyrimidines requires dihydropyrimidine dehydrogenase (DPD encoded by the DPYD gene) and reduced o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2082150ddaf9a34a99367b5c46759968
https://hdl.handle.net/1887/74788
https://hdl.handle.net/1887/74788
Autor:
Lunenburg, Carin A T C, Henricks, Linda M, Dreussi, Eva, Peters, Femke P, Fiocco, Marta, Meulendijks, Didier, Toffoli, Giuseppe, Guchelaar, Henk-Jan, Swen, Jesse J, Cecchin, Erika, Schellens, Jan H M, Gelderblom, Hans, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology
Publikováno v:
European Journal of Cancer, 104, 210. Elsevier Ltd
Background Prospective DPYD genotyping prevents severe fluoropyrimidine (FP)-induced toxicity by decreasing dosages in DPYD variant allele carriers. FP dosages in chemoradiation therapy (CRT) are lower than those in other FP-containing regimens. Phar
Autor:
Farzan, N., Vijverberg, S.J.H., Arets, H.G.M., Raaijmakers, J.A.M., van der Zee, A.H., Pharmacoepidemiology and Clinical Pharmacology, Afd Pharmacoepi & Clinical Pharmacology
Publikováno v:
Clinical and Experimental Allergy, 47(2), 271. Blackwell Publishing Ltd
BACKGROUND Pharmacogenetics studies of anti-inflammatory medication of asthma have expanded rapidly in recent decades, but the clinical value of their findings remains limited. OBJECTIVE To perform a systematic review of pharmacogenomics and pharmaco
Publikováno v:
Frontiers in Genetics, 10. Frontiers Media S. A.
Frontiers in Genetics
Frontiers in Genetics, 10. Frontiers Media S.A.
Frontiers in Genetics, Vol 10 (2019)
Frontiers in Genetics
Frontiers in Genetics, 10. Frontiers Media S.A.
Frontiers in Genetics, Vol 10 (2019)
Introduction: The Dutch Pharmacogenetics Working Group (DPWG) indicated a list of actionable genotypes that affect patients’ response to more 50 drugs; these drugs which show variable effects based on patients’ genetic traits were named as pharma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb06fd290bc0253bdb9b7d4a49d6ef35
https://dspace.library.uu.nl/handle/1874/408892
https://dspace.library.uu.nl/handle/1874/408892
Autor:
Alexander L T Imholz, Jesse J. Swen, Marlène H.W. van de Poel, Albert J. ten Tije, Paul Hamberg, Annemieke Cats, Femke M. de Man, Jos H. Beijnen, Miriam Koopman, Vincent O. Dezentjé, Emma Kienhuis, Caroline M.P.W. Mandigers, Peter Nieboer, Linda M. Henricks, Didier Meulendijks, André B.P. van Kuilenburg, Carin A.T.C. Lunenburg, Geert W.J. Frederix, Jan H.M. Schellens, Hilde Rosing, Henk-Jan Guchelaar, Helga J. Droogendijk, Rob L. H. Jansen, Frank J.F. Jeurissen, Ron H.J. Mathijssen, Hans Gelderblom, Arnold Baars, Geert Jan Creemers, Johanna E.A. Portielje, Erik van Werkhoven, Ron H.N. van Schaik
Publikováno v:
European Journal of Cancer, 107, 60. Elsevier Ltd
European Journal of Cancer, 107, 60. Elsevier Limited
European journal of cancer (Oxford, England, 107, 60-67. Elsevier Limited
European Journal of Cancer, 107, 60-67
European Journal of Cancer
European Journal of Cancer, 107, 60-67. Elsevier Ltd.
European Journal of Cancer, 107, 60-67. ELSEVIER SCI LTD
European Journal of Cancer, 107, 60. Elsevier Limited
European journal of cancer (Oxford, England, 107, 60-67. Elsevier Limited
European Journal of Cancer, 107, 60-67
European Journal of Cancer
European Journal of Cancer, 107, 60-67. Elsevier Ltd.
European Journal of Cancer, 107, 60-67. ELSEVIER SCI LTD
Background: Fluoropyrimidine therapy including capecitabine or 5-fluorouracil can result in severe treatment-related toxicity in up to 30% of patients. Toxicity is often related to reduced activity of dihydropyrimidine dehydrogenase, the main metabol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d1847de5cbd772fe5bd914816205b488
https://dspace.library.uu.nl/handle/1874/389408
https://dspace.library.uu.nl/handle/1874/389408